

# Amicus Therapeutics UK Operations Limited

---

Methodological note for HCP/ORDM/HCO disclosure – United Kingdom

## Definitions

### Recipients

Healthcare Organisation (HCO): a healthcare, medical or scientific association or organisation such as a hospital, clinic, foundation, university or other teaching institution or learned society whose business address, place of incorporation or primary place of operation is in the United Kingdom, or an organisation through which one or more health professionals or other relevant decision makers provide services whose business address, place of incorporation or primary place of operation is in the United Kingdom.

Healthcare Professional (HCP): any member of the medical, dental, pharmacy or nursing profession and any other person who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine. For disclosure, this also includes any Amicus employee whose primary occupation is that of a practising healthcare professional.

Other Relevant Decision Maker (ORDM): particularly includes someone with an NHS role who could influence administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who is not a health professional.

### Kind of ToVs

Transfers of Value include direct or indirect transfers, whether in cash, in-kind or otherwise, made in connection with the development or sale of medicines. ToVs may arise from the following broad types of activity (there are others):

- Contribution to costs related to events- Support providing or covering travel, accommodation and/or registration fees to support the attendance of an individual HCP or ORDM to an event organised or created by Amicus and/or a third party is included in the report.
- Fees for services and consultancy – Amicus engages Recipients for services when there is a genuine and legitimate business need and there is alignment with the expertise of the HCP. Recipients are paid for these services at a fair market value rate. Related expenses may also

be included as part of the contractual services in order for the Recipient to execute the assignment related to the contract. The ToV reported is the actual amount paid for payment services, and the related expenses.

- Research and Development - Transfers of Value to HCPs or HCOs related to the planning or conduct of non-clinical studies, clinical trials or non-interventions studies that are prospective in nature and that involve the collection of patient data from or on behalf of individuals, or groups of, HCPs specifically for the study. The disclosure includes both Amicus and CRO managed studies, investigator Initiated studies and academic research in the R&D section of the report.
- Market Research - ToVs might be made to HCPs in return for answering questions about Amicus products and / or a therapeutic area. Amicus generally participates in “double blinded” market research where it does not know the identities of the participants, and has therefore not reported any ToVs for these market research activities.
- Donations and grants – Donations and grants to HCOs, in cash or in kind that are freely given for the purpose of supporting healthcare, scientific research or education are included in the report. Donations to HCOs that are funded by employee contributions are not included in the report. Gift matching contributions from Amicus are reported.
- HCO Sponsorship – Sponsorship, including contributions to costs related to events/meetings paid to HCOs directly or indirectly via third parties organising events on behalf of an HCO are included in the report. This may include support of HCPs not known to Amicus via the HCO by way of registration fees, accommodation and travel. Subsistence provided to HCPs or ORDMs where they are supported to attend events/meetings are not reported.
- Collaborative Working – includes Joint Working, with HCOs and may also include patient organisations, in activities which either enhance patient care or are for the benefit of patients and/or benefit the HCO and as a minimum maintains patient care, where there is a shared commitment to successful delivery

## **Disclosure’s Scope**

### **Products concerned**

Prescription Only Medicines (POMs)

### **Company concerned**

Amicus Therapeutics UK Operations Limited and all Amicus affiliates making TOV’S to UK recipients

## **Excluded ToVs**

Amicus generally conducts double-blinded market research where HCP identities are not known; no ToVs are reported for these activities.

## **ToVs date**

Dates shown are the dates of payment to the recipient. Any payment made to a recipient within the reporting period is disclosed. For benefits in kind such as travel or accommodation, the payment date is the event date. For multi-year contracts, only ToVs made in the reporting period are included.

## **Direct ToVs**

Direct ToVs are those paid by an Amicus affiliate to a recipient (in cash, in-kind or otherwise). Categories include contributions to event costs (travel, accommodation, registration), fees for services/consultancy (at fair-market-value, including related expenses), donations and grants to HCOs, HCO sponsorship (including via third parties), collaborative working, and R&D.

## **Indirect ToVs**

Indirect ToVs are those made on behalf of an Amicus affiliate for the benefit of a recipient, or via a third party where the recipient is known or can be identified. These typically include (not exhaustive), costs related to HCP travel and accommodation; HCO sponsorship related to events and payments made to third parties in conjunction with Collaborative working.

## **Non-monetary ToVs**

Benefits in kind such as travel or accommodation are treated as ToVs and reported using the event date. We do not include Amicus personnel time costs as a ToV as part of collaborative working arrangements, but details of this are included in the executive summary.

## **ToVs in case of partial attendances or cancellation and refund**

The actual ToV amount is disclosed after adjusting for any cancellations or refunds.

## **Cross-border activities**

Amicus may contract HCPs from different countries to perform services in other markets. Some ToVs are made by an Amicus affiliate that is not the home country of the recipient. Disclosures of these ToVs are made in the recipient's home country (primary place of practice/registration).

## **R&D**

Transfers of Value to HCPs/HCOs related to non-clinical studies, clinical trials or prospective non-interventional studies involving patient data collection are included in the R&D section of the report. This includes Amicus- and CRO-managed studies, investigator-initiated studies and academic research.

## **Voluntary disclosure**

Not applicable

## **Specific considerations**

### **Country unique identifier**

Not applicable.

### **Self-incorporated HCP**

ToVs paid to a company owned by a healthcare professional are disclosed against the name of the individual HCP. ToVs to organisations not owned by an individual HCP are disclosed against the organisation's name, unless the organisation directs disclosure against the relevant HCP.

### **Multi-year agreements**

Only ToVs paid in the reporting period (2025) are disclosed for multi-year agreements.

### **Country specificities**

Not applicable

### **Quality Checks**

Internal company checks completed by dedicated personnel prior to disclosure and a third party company with expertise in disclosure also performs accuracy checks before publication. When possible, before publication, HCPs are also given an opportunity to check the information for accuracy and completeness. Disputes or requests related to the disclosure report can be sent to [Disclosure-ABPI@amicusrx.com](mailto:Disclosure-ABPI@amicusrx.com).

## **Data protection legal basis**

### **Consent collection**

Amicus relies on legitimate interests and does not collect consent for disclosure; opt-outs are assessed case-by-case as described below.

### **Legitimate interests**

ToVs are publicly disclosed on an individually named basis relying on legitimate interest under data privacy laws. Opt-out requests are assessed case by case using the ABPI Legitimate Interest toolkit and in line with data privacy law. Amicus does not permit partial individual disclosure; either all ToVs to a recipient in the period are disclosed individually, or all are disclosed in aggregate.

## Form of disclosure

### Date of publication

30/6/2026

### Disclosure platform

Disclosure UK – [www.disclosureuk.org.uk](http://www.disclosureuk.org.uk)

### Disclosure language

English.

## Disclosure financial data

### Currency

All ToVs are disclosed in GBP. If payments were made in another currency, amounts are converted based on the conversion rate on the date of payment; therefore totals may vary slightly from the exact local-currency amount.

### VAT included or excluded

Amicus reports ToVs exclusive of taxes.

### Calculation rules

Not applicable

## Additional Information

Dispute Management: prior to publication, HCPs may review data; if not contactable, the ABPI contacts them before publication. Disputes/requests: [Disclosure-ABPI@amicusrx.com](mailto:Disclosure-ABPI@amicusrx.com).  
Document Retention: five years following the disclosure year, aligned to ABPI retention.  
Approved: March 2025.

Amicus is proud to work with healthcare professionals for the benefit of patients. These interactions allow Amicus to gather advice and insights on topics including medicines development, patient treatment pathways, health economics and clinical best practice. This methodological note explains how Transfers of Value (ToVs) to HCPs, HCOs and ORDMs in the United Kingdom have been collated and reported.